Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft

Eugenia Raichlin, Krishnaswamy Chandrasekaran, Walter K. Kremers, Robert P. Frantz, Alfredo L. Clavell, Naveen L. Pereira, Richard J. Rodeheffer, Richard C. Daly, Christopher G A McGregor, Brooks S. Edwards, Sudhir S. Kushwaha

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

BACKGROUND.: Left ventricular hypertrophy (LVH) and diastolic dysfunction occur after cardiac transplantation. We investigated sirolimus (SRL) as primary immunosuppression for the attenuation of LVH and diastolic dysfunction of the cardiac allograft. METHODS.: Seventy cardiac transplant recipients were converted to SRL, 5.79±3.90 years after transplant, with complete calcineurin-inhibitor (CNI) withdrawal. Three consecutive echocardiographic studies, 1 year apart, were analyzed for changes in left ventricular (LV) mass and diastolic function during CNI and SRL treatment. RESULTS.: Changes in systolic (P=0.69) and diastolic blood pressures (BP) (P=0.32) did not differ between SRL and CNI treatment. LV mass and LV mass index increased (185.03±41.59-197.21±47.39 g, P=0.033 and 94.20±18.64-98. 93±20.08 g/m; P=0.030) during CNI and decreased (197.21±47.39-187. 59±48.88 g, P=0.025 and 98.93±20.08-94.06±20.31 g/m P=0.050) during SRL. The difference in ΔLV mass and ΔLV mass index was significant (P=0.011 and P=0.017, respectively) and was not associated with changes in BP. Left atrium volume index increased during CNI (46.73±16.3 5-54.20±18.47 cm/m, P=0.006) and decreased during SRL (54.20±18.47-49.75±18.40 cm/m, P=0.0036). The difference in left atrium (ΔLA) volume index was significant (P=0.002) and was not associated with changes in BP. CONCLUSIONS.: Withdrawal of CNI and replacement with SRL in cardiac transplant recipients results in a decrease in LV mass and improvement in diastolic function. SRL may be useful to attenuate LVH and improve cardiac allograft diastolic function.

Original languageEnglish (US)
Pages (from-to)1395-1400
Number of pages6
JournalTransplantation
Volume86
Issue number10
DOIs
StatePublished - Nov 27 2008

Fingerprint

Sirolimus
Immunosuppressive Agents
Allografts
Left Ventricular Hypertrophy
Blood Pressure
Heart Atria
Heart Transplantation
Immunosuppression
Calcineurin Inhibitors
Transplants
Therapeutics

Keywords

  • Cardiac allograft
  • Diastolic dysfunction
  • Left ventricular hypertrophy
  • Transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Raichlin, E., Chandrasekaran, K., Kremers, W. K., Frantz, R. P., Clavell, A. L., Pereira, N. L., ... Kushwaha, S. S. (2008). Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. Transplantation, 86(10), 1395-1400. https://doi.org/10.1097/TP.0b013e318189049a

Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. / Raichlin, Eugenia; Chandrasekaran, Krishnaswamy; Kremers, Walter K.; Frantz, Robert P.; Clavell, Alfredo L.; Pereira, Naveen L.; Rodeheffer, Richard J.; Daly, Richard C.; McGregor, Christopher G A; Edwards, Brooks S.; Kushwaha, Sudhir S.

In: Transplantation, Vol. 86, No. 10, 27.11.2008, p. 1395-1400.

Research output: Contribution to journalArticle

Raichlin, E, Chandrasekaran, K, Kremers, WK, Frantz, RP, Clavell, AL, Pereira, NL, Rodeheffer, RJ, Daly, RC, McGregor, CGA, Edwards, BS & Kushwaha, SS 2008, 'Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft', Transplantation, vol. 86, no. 10, pp. 1395-1400. https://doi.org/10.1097/TP.0b013e318189049a
Raichlin, Eugenia ; Chandrasekaran, Krishnaswamy ; Kremers, Walter K. ; Frantz, Robert P. ; Clavell, Alfredo L. ; Pereira, Naveen L. ; Rodeheffer, Richard J. ; Daly, Richard C. ; McGregor, Christopher G A ; Edwards, Brooks S. ; Kushwaha, Sudhir S. / Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. In: Transplantation. 2008 ; Vol. 86, No. 10. pp. 1395-1400.
@article{8b56fd56be8f4537a571760992208f08,
title = "Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft",
abstract = "BACKGROUND.: Left ventricular hypertrophy (LVH) and diastolic dysfunction occur after cardiac transplantation. We investigated sirolimus (SRL) as primary immunosuppression for the attenuation of LVH and diastolic dysfunction of the cardiac allograft. METHODS.: Seventy cardiac transplant recipients were converted to SRL, 5.79±3.90 years after transplant, with complete calcineurin-inhibitor (CNI) withdrawal. Three consecutive echocardiographic studies, 1 year apart, were analyzed for changes in left ventricular (LV) mass and diastolic function during CNI and SRL treatment. RESULTS.: Changes in systolic (P=0.69) and diastolic blood pressures (BP) (P=0.32) did not differ between SRL and CNI treatment. LV mass and LV mass index increased (185.03±41.59-197.21±47.39 g, P=0.033 and 94.20±18.64-98. 93±20.08 g/m; P=0.030) during CNI and decreased (197.21±47.39-187. 59±48.88 g, P=0.025 and 98.93±20.08-94.06±20.31 g/m P=0.050) during SRL. The difference in ΔLV mass and ΔLV mass index was significant (P=0.011 and P=0.017, respectively) and was not associated with changes in BP. Left atrium volume index increased during CNI (46.73±16.3 5-54.20±18.47 cm/m, P=0.006) and decreased during SRL (54.20±18.47-49.75±18.40 cm/m, P=0.0036). The difference in left atrium (ΔLA) volume index was significant (P=0.002) and was not associated with changes in BP. CONCLUSIONS.: Withdrawal of CNI and replacement with SRL in cardiac transplant recipients results in a decrease in LV mass and improvement in diastolic function. SRL may be useful to attenuate LVH and improve cardiac allograft diastolic function.",
keywords = "Cardiac allograft, Diastolic dysfunction, Left ventricular hypertrophy, Transplantation",
author = "Eugenia Raichlin and Krishnaswamy Chandrasekaran and Kremers, {Walter K.} and Frantz, {Robert P.} and Clavell, {Alfredo L.} and Pereira, {Naveen L.} and Rodeheffer, {Richard J.} and Daly, {Richard C.} and McGregor, {Christopher G A} and Edwards, {Brooks S.} and Kushwaha, {Sudhir S.}",
year = "2008",
month = "11",
day = "27",
doi = "10.1097/TP.0b013e318189049a",
language = "English (US)",
volume = "86",
pages = "1395--1400",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft

AU - Raichlin, Eugenia

AU - Chandrasekaran, Krishnaswamy

AU - Kremers, Walter K.

AU - Frantz, Robert P.

AU - Clavell, Alfredo L.

AU - Pereira, Naveen L.

AU - Rodeheffer, Richard J.

AU - Daly, Richard C.

AU - McGregor, Christopher G A

AU - Edwards, Brooks S.

AU - Kushwaha, Sudhir S.

PY - 2008/11/27

Y1 - 2008/11/27

N2 - BACKGROUND.: Left ventricular hypertrophy (LVH) and diastolic dysfunction occur after cardiac transplantation. We investigated sirolimus (SRL) as primary immunosuppression for the attenuation of LVH and diastolic dysfunction of the cardiac allograft. METHODS.: Seventy cardiac transplant recipients were converted to SRL, 5.79±3.90 years after transplant, with complete calcineurin-inhibitor (CNI) withdrawal. Three consecutive echocardiographic studies, 1 year apart, were analyzed for changes in left ventricular (LV) mass and diastolic function during CNI and SRL treatment. RESULTS.: Changes in systolic (P=0.69) and diastolic blood pressures (BP) (P=0.32) did not differ between SRL and CNI treatment. LV mass and LV mass index increased (185.03±41.59-197.21±47.39 g, P=0.033 and 94.20±18.64-98. 93±20.08 g/m; P=0.030) during CNI and decreased (197.21±47.39-187. 59±48.88 g, P=0.025 and 98.93±20.08-94.06±20.31 g/m P=0.050) during SRL. The difference in ΔLV mass and ΔLV mass index was significant (P=0.011 and P=0.017, respectively) and was not associated with changes in BP. Left atrium volume index increased during CNI (46.73±16.3 5-54.20±18.47 cm/m, P=0.006) and decreased during SRL (54.20±18.47-49.75±18.40 cm/m, P=0.0036). The difference in left atrium (ΔLA) volume index was significant (P=0.002) and was not associated with changes in BP. CONCLUSIONS.: Withdrawal of CNI and replacement with SRL in cardiac transplant recipients results in a decrease in LV mass and improvement in diastolic function. SRL may be useful to attenuate LVH and improve cardiac allograft diastolic function.

AB - BACKGROUND.: Left ventricular hypertrophy (LVH) and diastolic dysfunction occur after cardiac transplantation. We investigated sirolimus (SRL) as primary immunosuppression for the attenuation of LVH and diastolic dysfunction of the cardiac allograft. METHODS.: Seventy cardiac transplant recipients were converted to SRL, 5.79±3.90 years after transplant, with complete calcineurin-inhibitor (CNI) withdrawal. Three consecutive echocardiographic studies, 1 year apart, were analyzed for changes in left ventricular (LV) mass and diastolic function during CNI and SRL treatment. RESULTS.: Changes in systolic (P=0.69) and diastolic blood pressures (BP) (P=0.32) did not differ between SRL and CNI treatment. LV mass and LV mass index increased (185.03±41.59-197.21±47.39 g, P=0.033 and 94.20±18.64-98. 93±20.08 g/m; P=0.030) during CNI and decreased (197.21±47.39-187. 59±48.88 g, P=0.025 and 98.93±20.08-94.06±20.31 g/m P=0.050) during SRL. The difference in ΔLV mass and ΔLV mass index was significant (P=0.011 and P=0.017, respectively) and was not associated with changes in BP. Left atrium volume index increased during CNI (46.73±16.3 5-54.20±18.47 cm/m, P=0.006) and decreased during SRL (54.20±18.47-49.75±18.40 cm/m, P=0.0036). The difference in left atrium (ΔLA) volume index was significant (P=0.002) and was not associated with changes in BP. CONCLUSIONS.: Withdrawal of CNI and replacement with SRL in cardiac transplant recipients results in a decrease in LV mass and improvement in diastolic function. SRL may be useful to attenuate LVH and improve cardiac allograft diastolic function.

KW - Cardiac allograft

KW - Diastolic dysfunction

KW - Left ventricular hypertrophy

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=58149349850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149349850&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e318189049a

DO - 10.1097/TP.0b013e318189049a

M3 - Article

VL - 86

SP - 1395

EP - 1400

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -